Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: drug prices

Biosimilar Prescribing Habits in the VA & Academic Settings

Arthritis & Rheumatology  |  June 29, 2020

In a new study, Baker et al. examined reference product and biosimilar orders, comparing data from a Veterans Affairs Medical Center (VAMC) to those from an academic medical center…

Filed under:Biologics/DMARDsDrug UpdatesResearch Rheum Tagged with:Arthritis & RheumatologyBiosimilarsprescribingResearch

Medicalwriters/Science Source

Biosimilars Are Slowly Climbing Toward Acceptance in Rheumatology

Bryn Nelson, PhD  |  June 15, 2020

As useful stand-ins for biologics targeting a range of inflammatory diseases, biosimilars have made significant inroads across Europe as less expensive alternatives. Denmark, for example, realized a cost savings of 64% after instituting a mandatory national switch from the originator infliximab to its biosimilar counterpart. In the U.S., however, a considerably smaller fraction of rheumatologists…

Filed under:Biologics/DMARDsResearch Rheum Tagged with:Arthritis & Rheumatologydrug costsinfliximab

Coverage & Reimbursement Challenges: Updates from the ACR Insurance Subcommittee Chair

Chris Phillips, MD  |  February 7, 2020

The ACR Insurance Subcommittee is working to address specialty pharmacy requirements for in-office treatments, elimination of consultation codes and other coverage and reimbursement challenges.

Filed under:Billing/CodingInsuranceLegislation & Advocacy Tagged with:ACR Insurance Subcommittee (ISC)Consultation CodesDr. Chris Phillipsmodifier 25specialty drug acquisition

Are Your Patients at Risk? Advocacy Matters

Kimberly Retzlaff  |  February 6, 2020

When insurance company practices put patients at risk, advocacy is an important tool physicians can use to make a real difference. You can make a difference.

Filed under:InsuranceLegislation & Advocacy Tagged with:ACR Insurance Subcommittee (ISC)AdvocacyBrian LogginsChris MorrisDr. Chris PhillipsGovernment Affairs Committee (GAC)Norman B. Gaylis

Biologic Spending & Price Trends

Arthritis & Rheumatology  |  January 28, 2020

Any given rheumatology patient who needs a biologic disease-modifying anti-rheumatic drug (DMARD) will spend $22,000–44,000 on their medication each year…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabbiologic drugsDisease-modifying antirheumatic drugs (DMARDs)etanerceptinfliximab

Rep. Schofield and Dr. Worthing listen to an audience member's question.

1 Person Can Make a Difference: The Importance of Advocacy

Keri Losavio  |  November 11, 2019

Your voice matters: That was the shared theme of presentations by Angus Worthing, MD, FACR, FACP, William F. Harvey, MD, MSc, FACR, and Georgia Rep. Kim Schofield (D-Atlanta, Dist. 60) in the session, Raise Your Voice! Advocacy Update from Government Affairs at the 2019 ACR/ARP Annual Meeting on Monday, Nov. 11.

Filed under:American College of RheumatologyLegislation & AdvocacyMeeting ReportsProfessional Topics Tagged with:2019 ACR/ARP Annual MeetingAdvocacyDr. Will HarveyDr. WorthingRepresentative Kim Schofield

The Cost of Free Pharmaceutical Services

Philip Seo, MD, MHS  |  October 18, 2019

The cards sat, untouched, in a corner of my desk. In the 1800s, it was common for American saloons to provide patrons with a free meal. Of course, the meal came with a catch: The meals were predictably salt laden and designed to encourage patrons to drink more beer. Hence was born the expression, “There…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:GoodRxpharmacy benefit administratorspharmacy benefit managers (PBMs)

Trump Administration Proposes Changes to Healthcare Anti-Kickback Rules

Carl O'Donnell  |  October 15, 2019

(Reuters)—The Trump administration has proposed changes to federal anti-kickback provisions that restrict the kinds of patient referrals doctors can make, saying it will improve healthcare coordination and foster payments based on the quality of care. The plan will change how the U.S. Department of Health and Human Services (HHS) enforces the Physician Self Referral Law,…

Filed under:Professional Topics Tagged with:Anti-Kickback StatuteStark LawTrump administration

Rheumatology Patients & Providers Push for Step Therapy, Workforce Changes

Kelly Tyrrell  |  September 20, 2019

Rheumatology professional and patients visited with 117 legislators and their staffs during the 2019 Advocates for Arthritis event to champion better rheumatology patient care and access.

Filed under:Legislation & Advocacy Tagged with:Advocacy 101Advocates for ArthritisRheumPAC

Bending, Not Breaking

Philip Seo, MD, MHS  |  August 16, 2019

“And of course, I am not telling you to do it. That would be illegal.” As a general rule, I try not to instruct my patients to break the law. My business model depends on repeat customers, so placing a patient at risk of getting arrested—even if that risk is remote—doesn’t seem like a good…

Filed under:EthicsOpinionRheuminationsSpeak Out Rheum Tagged with:Canadian drugsdrug costs

  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 25
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences